Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.

A, Colao; MD, Bronstein; P, Freda; F, Gu; CC, Shen; M, Gadelha; M, Fleseriu; der Lely AJ, van; AJ, Farrall; Reséndiz K, Hermosillo; M, Ruffin; Y, Chen; M, Sheppard

doi:10.1210/jc.2013-2480

Public

Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.

Shared by NobleBlocks on Jan 13, 2014 • 12:00 AM UTC

Authors:

Colao A

Bronstein MD

Freda P

Abstract

Context Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control.Objective Our objective was to demonstrate the s...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!